Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has settled its patent litigation with MedImmune involving the Cabilly patent, which is co-owned by Genentech and City of Hope and relates in part to methods of producing antibodies.
Subscribe to our email newsletter
Under the terms of the settlement agreement, the litigation, which was pending before the US District Court of California, has now been fully resolved and dismissed.
The settlement resolves disputed issues with respect to MedImmune’s marketed product Synagis (palivizumab) as well as a related product (motavizumab) for which MedImmune is seeking regulatory approval.
The settlement also permits MedImmune to obtain licenses for certain additional pipeline products under the Cabilly patent family.